The China Longitudinal Aging Study of Cognitive Impairment

Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine

Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. Based on the above understanding, the study carry out the population cohort study based on accurate diagnosis and construct the high standard information and sample bank. The study will establish the standard and quality system of geriatric cognitive disorders cohort study (unified standards and norms). The study will integrate the standard biological samples stratified acquisition function module (homogeneity and precision) of elderly cognitive disorders, and complete the construction of biological samples bank and clinical diagnosis and treatment information database. The study will apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study will evaluate whether peripheral nerve degeneration can predict central nervous system degeneration based on the large cohort of elderly study. In addition, The study will make an effective supplement the sample bank construction of Shanghai Mental Health Center.

Study Overview

• Status: Recruiting
• Conditions: Depression; Anxiety; Alzheimer Disease; Mild Cognitive Impairment; Dementia, Vascular; Dementia With Lewy Bodies; Dementia Frontal
• Intervention / Treatment: Other: Naturalistic observation

Detailed Description

The neuropsychological test battery are used to access the cognitive function of subjects in the study. The brain MRI and biochemical examination will be done in the screening period. The samples such as plasma, serum, urine and faeces et al. of the subjects will be collected in the study.

• Study Type: Observational
• Enrollment (Anticipated): 10000

Contacts and Locations

• Study Contact: Name: Shifu Xiao, M.D., Ph.D.; Phone Number: 73441 00862164387250; Email: xiaoshifu@msn.com
• Study Contact Backup: Name: Tao Wang, M.D., Ph.D.; Phone Number: 73220 00862164387250; Email: wtshhwy@163.com

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200030
      • Recruiting
      • SHANGHAI MENTAL HEALTH CENTRE
      • Contact: Shifu Xiao, M.D., Ph.D.
      • Sub-Investigator: Tao Wang, M.D., Ph.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

10,000 adult Chinese aged 60 and up who have been living Shanghai will be recruited.

Description

Inclusion Criteria:

• registered residents in the community;
• ≥ 60 years;
• without schizophrenia or mental retardation;
• be able to communicate and accept physical and cognitive examinations

Exclusion Criteria:

• blind
• deaf mute

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Neurocognitive disorder; Dementias	Other: Naturalistic observation; Naturalistic observation; Other Names: Normal Aging
Normal Aging; Normal Aging with normal cognitive function	Other: Naturalistic observation; Naturalistic observation; Other Names: Normal Aging

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence, incidence of neurocognitive disorder	Prevalence, incidence of neurocognitive disorder such as AD, MCI and other types of dementia	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence, incidence of mood disorder	Prevalence, incidence of mood disorder such as depression, anxiaty	5 years
conversion rate	conversion rate of neurocognitive disorder from Normal Elderly	5 years

Collaborators and Investigators

• Sponsor: Shanghai Mental Health Center
• Investigators: Principal Investigator: Huafang Li, M.D., Ph.D., SHANGHAI MENTAL HEALTH CENTRE

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 1, 2018
• Primary Completion (ANTICIPATED): November 30, 2023
• Study Completion (ANTICIPATED): November 30, 2023

Study Registration Dates

• First Submitted: January 26, 2018
• First Submitted That Met QC Criteria: September 13, 2018
• First Posted (ACTUAL): September 14, 2018

Study Record Updates

• Last Update Posted (ACTUAL): January 10, 2020
• Last Update Submitted That Met QC Criteria: January 8, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: dementia; depression; cohort study; brain imaging; precision diagnosis; sample bank
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Neurocognitive Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Tauopathies; Cognition Disorders; Intracranial Arterial Diseases; Intracranial Arteriosclerosis; Leukoencephalopathies; Depression; Dementia; Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease; Dementia, Vascular
• Other Study ID Numbers: CRC2017ZD02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No